Research Analysts Offer Predictions for MMSI Q2 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Analysts at Zacks Research reduced their Q2 2026 EPS estimates for Merit Medical Systems in a research note issued to investors on Thursday, May 21st. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $0.86 for the quarter, down from their previous forecast of $0.94. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.61 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q4 2026 earnings at $0.99 EPS, FY2026 earnings at $3.57 EPS, Q3 2027 earnings at $0.98 EPS, Q1 2028 earnings at $0.93 EPS and FY2028 earnings at $4.12 EPS.

Several other equities analysts have also recently weighed in on the company. Wells Fargo & Company lowered their price target on Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Needham & Company LLC dropped their price target on shares of Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Compass Point set a $107.00 target price on Merit Medical Systems in a research report on Monday, April 20th. Piper Sandler cut their target price on shares of Merit Medical Systems from $106.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $92.80.

Merit Medical Systems Stock Performance

Shares of NASDAQ MMSI opened at $64.52 on Wednesday. The company has a market cap of $3.85 billion, a PE ratio of 27.93, a PEG ratio of 2.00 and a beta of 0.58. The firm’s 50-day moving average price is $66.68 and its 200-day moving average price is $77.39. Merit Medical Systems has a 52-week low of $59.74 and a 52-week high of $97.18. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, beating the consensus estimate of $0.84 by $0.10. The business had revenue of $381.88 million for the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The company’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business posted $0.86 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS.

Institutional Investors Weigh In On Merit Medical Systems

Institutional investors and hedge funds have recently modified their holdings of the business. Los Angeles Capital Management LLC acquired a new position in Merit Medical Systems in the fourth quarter valued at approximately $25,000. Maseco LLP bought a new stake in shares of Merit Medical Systems during the 4th quarter valued at $26,000. Torren Management LLC acquired a new position in shares of Merit Medical Systems in the 4th quarter valued at $38,000. Covestor Ltd boosted its position in shares of Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares during the last quarter. Finally, Danske Bank A S bought a new position in shares of Merit Medical Systems in the 3rd quarter worth $42,000. 99.66% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Brian G. Lloyd bought 2,000 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was bought at an average cost of $62.62 per share, with a total value of $125,240.00. Following the completion of the purchase, the insider owned 2,000 shares in the company, valued at approximately $125,240. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director directly owned 7,809 shares in the company, valued at approximately $488,921.49. This represents a 39.04% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.